Current landscape in antiviral drug development against herpes simplex virus infections

Current landscape in antiviral drug development against herpes simplex virus infections

Abstract Herpes simplex viruses (HSV) are common human pathogens with a combined global seroprevalence of 90% in the adult population. HSV‐1 causes orofacial herpes but can cause severe diseases, such as the potentially fatal herpes encephalitis and herpes keratitis, a prevalent cause of infectious...

Full description

Bibliographic Details
Main Authors: Fanny Frejborg, Kiira Kalke, Veijo Hukkanen
Format: Article
Language:English
Published: Wiley-VCH 2022-12-01
Series:Smart Medicine
Subjects:
antiviral therapies
clinical trials
drug development
herpes simplex virus
HSV
infections
Online Access:https://doi.org/10.1002/SMMD.20220004

Internet

https://doi.org/10.1002/SMMD.20220004

Similar Items